The patient’s dilemma: Where should I donate my GIST tissue?
The fact is GIST is a rare disease and as a result researchers simply do not have enough GIST tissue samples to do the research needed to find a cure. “Too many people are still [...]
Joseph R. Mirenda, III – In Memoriam
Joseph R. Mirenda III, 68, husband of the late Margaret E. (Reese) Mirenda, Old Swede Road, Douglassville, died April 16, 2009, of natural causes in his residence.
Liz Skree at the NIH Pediatric & Wild-type GIST Clinic
Liz Skree at the NIH Pediatric & Wild-type GIST Clinic
Leah Knopp at the NIH Pediatric & Wild-type GIST Clinic
Leah Knopp at the NIH Pediatric & Wild-type GIST Clinic
Josalin Dunn at the NIH Pediatric and Wild-type GIST Clinic
Josalin Dunn at the NIH Pediatric & Wild-type GIST Clinic
Questions to Consider for Adjuvant Treatment
GIST patients face many decisions about their treatment. Many GIST patients have surgery to remove a primary tumor and do not have detectable metastases at the time of surgery. This large group of patients faces the decision of whether or not to take Gleevec to try to prevent or delay a recurrence. Adjuvant therapy refers to additional treatment given after a main mode of therapy (the main treatment is usually surgery). For example, Gleevec given after surgery in hopes of preventing or delaying a recurrence is called adjuvant therapy.
Ellen Sarko Heppler – In Memoriam
Mrs. Ellen Marie Sarko Heppler, 47, of Jamestown, North Carolina, died on December 7, 2008 at her residence. A native of Cuyahoga County, Ohio, she was born on July 9, 1960, a daughter of James A. and Betty Mash Sarko. Ellen’s family and home were her first love.
$2 million pledged for GIST research
Novartis CEO Dr. Daniel Vasella made the commitment in Boston after hearing a plea from Life Raft Executive Director Norman Scherzer. The $2 million grant is the largest single donation for GIST [...]